Get the Stockscreener App
11.47
3.62%
0.41
Eikon Therapeutics Inc stock is traded at $11.47, with a volume of 362.64K.
It is up +3.62% in the last 24 hours and down -23.04% over the past month.
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
See More
Previous Close:
$11.06
Open:
$10.97
24h Volume:
362.64K
Relative Volume:
1.85
Market Cap:
$618.93M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-2.39%
1M Performance:
-23.04%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$10.97
$11.84
1-Week Range:
$10.90
$12.24
52-Week Range:
$10.82
$16.50
Eikon Therapeutics Inc Stock (EIKN) Company Profile
Compare EIKN vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EIKN
Eikon Therapeutics Inc
|
11.46 | 597.07M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
458.44 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.63 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
326.51 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
695.56 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.61 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Eikon Therapeutics Inc Stock (EIKN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Initiated | BofA Securities | Buy |
| Mar-02-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-02-26 | Initiated | JP Morgan | Overweight |
| Mar-02-26 | Initiated | Mizuho | Outperform |
| Mar-02-26 | Initiated | Morgan Stanley | Overweight |
| Feb-26-26 | Initiated | Wedbush | Underperform |
View All
Eikon Therapeutics Inc Stock (EIKN) Latest News
Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to S&P TMI Index - marketscreener.com
Eikon Therapeutics (EIKN) Stock Analysis Report | Financials & Insights - Benzinga Japan
Eikon Therapeutics (EIKN) grants 25,873-share stock option award to director - Stock Titan
Eikon Therapeutics (EIKN) grants director Kenneth Frazier 25,873 options - Stock Titan
Large stock option grant to Eikon Therapeutics (EIKN) director and officer - Stock Titan
Eikon Therapeutics (EIKN) COO awarded 87,157-share stock option grant - Stock Titan
Eikon Therapeutics Shares Jump 6% as Brokerages Initiate Coverage By Investing.com - Investing.com Canada
Eikon Therapeutics Shares Jump 6% as Brokerages Initiate Coverage - Investing.com UK
BofA initiates Eikon Therapeutics stock with buy rating on platform potential - Investing.com Australia
BofA Securities Initiates Eikon Therapeutics at Buy With $34 Price Target - marketscreener.com
Cantor Fitzgerald Initiates Eikon Therapeutics at Overweight - marketscreener.com
This NextTrip Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Mizuho Initiates Eikon Therapeutics at Outperform With $26 Price Target - marketscreener.com
BofA initiates Eikon Therapeutics stock with buy rating on platform potential By Investing.com - Investing.com South Africa
Morgan Stanley Initiates Eikon Therapeutics at Overweight With $32 Price Target - marketscreener.com
Mizuho initiates Eikon Therapeutics stock coverage with outperform - Investing.com Nigeria
JPMorgan initiates Eikon Therapeutics stock at Overweight By Investing.com - Investing.com Nigeria
Morgan Stanley initiates Eikon Therapeutics stock coverage at overweight By Investing.com - Investing.com South Africa
Morgan Stanley initiates Eikon Therapeutics stock coverage at overweight - Investing.com India
JPMorgan initiates Eikon Therapeutics stock at Overweight - Investing.com UK
Bank of America Global Research recently announced the official initiation of research coverage on biotechnology company Eikon Therapeutics (stock code: EIKN), and assigned an initial "Buy" rating. - Bitget
Bay Area life sciences firms raise $6.1B as three companies go public - The Business Journals
Eikon Therapeutics, Inc.Common Stock (NQ: EIKN - The Chronicle-Journal
Eikon Therapeutics, Inc.: Dividend historical data and projections - marketscreener.com
Eikon Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | EIKN | US2825641036 - marketscreener.com
Eikon Therapeutics stock drops after Wedbush downgrade By Investing.com - Investing.com Australia
Eikon Therapeutics stock drops after Wedbush downgrade - Investing.com South Africa
Wedbush initiates Eikon Therapeutics stock with underperform rating - Investing.com South Africa
Wedbush initiates Eikon Therapeutics stock with underperform rating By Investing.com - Investing.com Australia
User - The Chronicle-Journal
EIKN Should I Buy - Intellectia AI
ADIA and Platinum Falcon disclose 2.82M EIKN shares (ADIA affiliate ownership) - Stock Titan
EIKN SEC FilingsEikon Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
What is the current Price Target and Forecast for Eikon Therapeutics, Inc. (EIKN) - Zacks Investment Research
Insider Stock Purchases: February 10, 2026 - Quiver Quantitative
Eikon Therapeutics Prices $381 Million Initial Public Offering - Global Legal Chronicle
Wall Street Braces For IPO Boom: Goldman Says 2026 Listings Could Hit $160 Billion As Tech, AI Lead - Benzinga
Merck veteran-led Eikon seeks $908M valuation in US IPO - MSN
Eikon Therapeutics completes IPO and updates governance documents - The Globe and Mail
Eikon, Agomab raise $350M total in IPOs, sink in aftermarket: Public Equity Report - biocentury.com
Eikon Therapeutics, Inc (EIKN) Stock Price Today & Analysis - Gotrade
Finance Watch: Four IPOs In One Week - Citeline News & Insights
Merck veteran Perlmutter-led Eikon Therapeutics valued at $860 million in Nasdaq debut - WTAQ
It was supposed to be the biggest week for IPOs in years. But a 'selective' market didn't cooperate - The Business Journals
Eikon Therapeutics, Late-Stage Clinical Oncology Drug Developer, Files for Nasdaq IPO - TradingView
Eikon Therapeutics valued at $860 million in Nasdaq debut - marketscreener.com
Eikon Therapeutics Inc Stock (EIKN) Financials Data
There is no financial data for Eikon Therapeutics Inc (EIKN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):